Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Sweetening the hallmarks of cancer: Galectins as multifunctional mediators of tumor progression.

Girotti MR, Salatino M, Dalotto-Moreno T, Rabinovich GA.

J Exp Med. 2020 Feb 3;217(2). pii: e20182041. doi: 10.1084/jem.20182041.

PMID:
31873723
2.

[Immunotherapy in cancer. Current prospects, challenges and new horizons].

Dalotto-Moreno T, Blidner AG, Girotti MR, Maller SM, Rabinovich GA.

Medicina (B Aires). 2018;78(5):336-348. Review. Spanish.

3.

Only a subpopulation of mouse sperm displays a rapid increase in intracellular calcium during capacitation.

Luque GM, Dalotto-Moreno T, Martín-Hidalgo D, Ritagliati C, Puga Molina LC, Romarowski A, Balestrini PA, Schiavi-Ehrenhaus LJ, Gilio N, Krapf D, Visconti PE, Buffone MG.

J Cell Physiol. 2018 Dec;233(12):9685-9700. doi: 10.1002/jcp.26883. Epub 2018 Jun 28.

4.

Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk.

Orozco CA, Martinez-Bosch N, Guerrero PE, Vinaixa J, Dalotto-Moreno T, Iglesias M, Moreno M, Djurec M, Poirier F, Gabius HJ, Fernandez-Zapico ME, Hwang RF, Guerra C, Rabinovich GA, Navarro P.

Proc Natl Acad Sci U S A. 2018 Apr 17;115(16):E3769-E3778. doi: 10.1073/pnas.1722434115. Epub 2018 Apr 3.

5.

Regulation of galectins by hypoxia and their relevance in angiogenesis: strategies and methods.

Salatino M, Croci DO, Laderach DJ, Compagno D, Gentilini L, Dalotto-Moreno T, Dergan-Dylon LS, Méndez-Huergo SP, Toscano MA, Cerliani JP, Rabinovich GA.

Methods Mol Biol. 2015;1207:293-304. doi: 10.1007/978-1-4939-1396-1_19.

PMID:
25253148
6.

Study of galectins in tumor immunity: strategies and methods.

Cerliani JP, Dalotto-Moreno T, Compagno D, Dergan-Dylon LS, Laderach DJ, Gentilini L, Croci DO, Méndez-Huergo SP, Toscano MA, Salatino M, Rabinovich GA.

Methods Mol Biol. 2015;1207:249-68. doi: 10.1007/978-1-4939-1396-1_16.

PMID:
25253145
7.

Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors.

Croci DO, Cerliani JP, Dalotto-Moreno T, Méndez-Huergo SP, Mascanfroni ID, Dergan-Dylon S, Toscano MA, Caramelo JJ, García-Vallejo JJ, Ouyang J, Mesri EA, Junttila MR, Bais C, Shipp MA, Salatino M, Rabinovich GA.

Cell. 2014 Feb 13;156(4):744-58. doi: 10.1016/j.cell.2014.01.043.

8.

Expansion of CD11b(+)Ly6G (+)Ly6C (int) cells driven by medroxyprogesterone acetate in mice bearing breast tumors restrains NK cell effector functions.

Spallanzani RG, Dalotto-Moreno T, Raffo Iraolagoitia XL, Ziblat A, Domaica CI, Avila DE, Rossi LE, Fuertes MB, Battistone MA, Rabinovich GA, Salatino M, Zwirner NW.

Cancer Immunol Immunother. 2013 Dec;62(12):1781-95. doi: 10.1007/s00262-013-1483-x. Epub 2013 Oct 11.

PMID:
24114144
9.

Thwarting galectin-induced immunosuppression in breast cancer.

Salatino M, Dalotto-Moreno T, Rabinovich GA.

Oncoimmunology. 2013 May 1;2(5):e24077.

10.

Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease.

Dalotto-Moreno T, Croci DO, Cerliani JP, Martinez-Allo VC, Dergan-Dylon S, Méndez-Huergo SP, Stupirski JC, Mazal D, Osinaga E, Toscano MA, Sundblad V, Rabinovich GA, Salatino M.

Cancer Res. 2013 Feb 1;73(3):1107-17. doi: 10.1158/0008-5472.CAN-12-2418. Epub 2012 Nov 29.

Supplemental Content

Loading ...
Support Center